Side-by-side comparison
Eli Lilly and vs Merck & Co.
As of Sep 25, 2026, P/E is 39.7x for Eli Lilly and vs 119.0x for Merck & Co.; P/S is 14.0x for Eli Lilly and vs 5.5x for Merck & Co.; revenue growth is 49.6% for Eli Lilly and vs 4.6% for Merck & Co.; net margin is 33.5% for Eli Lilly and vs 4.8% for Merck & Co..
Key metrics
| Metric | LLY | MRK |
|---|---|---|
| Price | $1,183.46 | $148.78 |
| Market cap | $1.11T | $367.07B |
| P/E | 39.7x (#1) | 119.0x (#2) |
| P/S | 14.0x (#2) | 5.5x (#1) |
| Revenue growth | 49.6% (#1) | 4.6% (#2) |
| Operating margin | — | — |
| Net margin | 33.5% (#1) | 4.8% (#2) |
| Debt / equity | 1.41 (#2) | 1.22 (#1) |
| 1-year return | +63.3% (#2) | +89.4% (#1) |
| Research score | 69/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Eli Lilly and Company (LLY) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General